CVS Health sees 2022 profit meeting Street estimates as COVID-19 costs subside
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
CVS Health (CVS) PT Raised to $115 at Cantor Fitzgerald
November 3, 2021 1:33 PM EDTCantor Fitzgerald analyst Steven Halper raised the price target on CVS Health (NYSE: CVS) to $115.00 (from $95.00) while maintaining an Overweight rating following earnings.
The analyst commented, "We reiterate our Overweight rating on CVS shares and increase our 12-month price target to $115 from $95.... More
CVS Health (CVS) Announces Availability of Pfizer-BioNTech COVID-19 Vaccine to Children Aged 5-11
November 3, 2021 10:01 AM EDTCVS Health (NYSE: CVS) today announced that select CVS Pharmacy locations will be offering a two-dose primary series of the Pfizer-BioNTech COVID-19 pediatric vaccine to children ages five to 11 years of age starting on Sunday, 11/7, upon receipt and confirmation of vaccine supply. This follows authorization of the vaccine by the Centers for Disease Control and Prevention (CDC) based on guidance from the organization's Advisory Committee on Immunization Practices and Food and Drug Administration (FDA) Emergency Use Authorization. Parental or legal guardian consent is required for this age group, and children must be... More
